NewLink Genetics in Ames, Iowa, has grabbed $7.5 million in a Series D financing designed to accelerate the clinical development of its therapeutic cancer products. The financing involved additional funding from prior investors."NewLink has worked hard to become one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, chairman and CEO. "The proceeds of this financing will allow us to both rapidly move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our IDO inhibitor, D-1MT, into multiple Phase II studies." NewLink release